摘要
目的 探讨奥沙利铂及卡培他滨新辅助化疗对局部进展期低位直肠癌患者排便功能及预后的影响。方法 选取2021年5月至2022年11月泰安市肿瘤防治院收治的112例局部进展期低位直肠癌患者作为研究对象,随机分为A组与B组,各56例。A组予以5-氟尿嘧啶、亚叶酸钙和奥沙利铂共同新辅助化疗,B组行卡培他滨、奥沙利铂共同新辅助化疗,比较两组的化疗效果。结果 B组近期疗效治疗有效率高于A组,差异有统计意义(P<0.05)。进行为期1年随访,相比A组,B组局部复发率更低,总生存率更高,差异有统计学意义(P<0.05)。化疗后B组CD3^(+)、CD4^(+)均高于A组,CD8^(+)低于A组,差异有统计学意义(P<0.05)。化疗后,B组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)水平低于A组,差异有统计学意义(P<0.05)。B组不良反应发生率低于A组,差异有统计学意义(P<0.05)。化疗后B组基质金属蛋白酶-9(MMP-9)水平低于A组,微管相关肿瘤抑制因子1(MTUS1)、半胱氨酸天冬氨酸蛋白水解酶-3(Caspase-3)、E-钙黏蛋白(E-cadherin)和Runt相关转录因子3(Runx3)水平高于A组,差异有统计学意义(P<0.05)。结论 治疗局部进展期低位直肠癌时,开展新辅助化疗(卡培他滨联合奥沙利铂),近期效果理想,同时可使患者免疫能力增强,降低血清肿瘤标志物水平,改善预后,且安全性较高。
Objective To explore the effect of oxaliplatin and capecitabine neoadjuvant chemotherapy on defecation function and prognosis in patients with locally advanced low rectal cancer.Methods A total of 112 patients with locally advanced low rectal cancer admitted to Tai 'an Cancer Prevention and Control Hospital from May 2021 to November 2022 were selected as the study objects and randomly divided into group A and Group B,with 56 cases each.Group A received 5-fluorouracil,calcium folinate and oxaliplatin combined neoadjuvant chemotherapy,group B received capecitabine and oxaliplatin combined neoadjuvant chemotherapy,and the chemotherapy effect of the two groups was compared.Results The short-term efficacy of group B was higher than that of group A,and the difference was statistically significant(P<0.05).After 1-year follow-up,compared with group A,group B had lower local recurrence rate and higher overall survival rate,and the difference was statistically significant(P<0.05).After chemotherapy,CD3^(+) and CD4^(+) in group B were higher than those in group A,and CD8^(+) was lower than those in group A,the difference was statistically significant(P<0.05).After chemotherapy,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125) and carbohydrate antigen 19-9(CA19-9) in group B were lower than those in group A,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in group B was lower than that in group A,and the difference was statistically significant(P<0.05).After chemotherapy,the level of matrix metalloproteinase-9(MMP-9) in group B was lower than that in group A,and the levels of microtubule-associated tumor suppressor factor 1(MTUS1),Caspase-3(Caspase-3),E-cadherin and RUNt-associated transcription factor 3(Runx3) in group B were higher than those in group A,the difference was statistically significant(P<0.05).Conclusion In the treatment of locally advanced low rectal cancer,neoadjuvant chemotherapy(capecitabine combined with oxaliplatin) has a good short-te
作者
王娟
WANG Juan(Department 2 of Chemotherapy,Tai'an Cancer Prevention and Control Hospital,Tai'an 271000,China)
出处
《中国药物经济学》
2024年第5期90-93,100,共5页
China Journal of Pharmaceutical Economics
关键词
局部进展期
新辅助化疗
卡培他滨
低位直肠癌
奥沙利铂
Local progression stage
Neoadjuvant chemotherapy
Capecitabine
Low rectal cancer
Oxaliplatin